As the FDA is poised to authorize the new Pfizer and Merck pills to treat those with Covid-19 who haven’t been hospitalized, Bloomberg reports that the US will only have limited supplies of each pill…
The FDA on Wednesday signed off on Pfizer’s Covid-19 pills, which are meant to help keep people out of the hospital. The news comes at a crucial moment, as the Omicron variant has taken over Delta as…
Biopharmas are not immune to the “Great Resignation” spurred by the pandemic, and drug developers will have to create new formulations to attract and retain talent, or at least improve current hiring…
Longevity and mental health biotechs take note: Korify Capital is putting together a $100 million venture fund targeting your space and is looking to build a portfolio of 15 to 20 companies across…
Philips has scored a de novo clearance from the FDA for the first laser-based device for removing blood vessel filter implants that aim to strain out traveling blood clots before they damage the lungs…
The data are clear: White patients make up the majority in clinical trials. But the drug development industry—despite a lot of progress and an awareness among the largest pharmas out there—still…
Stephen Gillett’s annual evaluation must have gone well: After just one year as chief operating officer at Verily, he’s been promoted to take on the role of president, too.
Curebase, which is focused on siteless clinical trials, has joined the WCG Avoca Quality Consortium that boasts more than 175 pharma, biotech, clinical site and CRO organizations.
One antitrust probe down, one more to go for Microsoft and its $19.7 billion bid to buy Nuance Communications.
Gyroscope Therapeutics has been spun this way and that in 2021, going from a $148 million raise to a failed IPO to a $40 million investment from Sanofi in quick succession. But Novartis has ensured…
